Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Zimmer Biomet (NYSE:ZBH) issued its earnings results on Tuesday. The medical equipment provider reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04, FiscalAI reports. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. Zimmer Biomet updated its FY 2026 guidance to 8.300-8.450 EPS.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $89.64 on Tuesday. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The stock has a 50 day moving average of $90.02 and a 200-day moving average of $95.68. The stock has a market cap of $17.76 billion, a P/E ratio of 22.19, a price-to-earnings-growth ratio of 2.29 and a beta of 0.62. Zimmer Biomet has a 52 week low of $84.59 and a 52 week high of $114.44.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is 23.76%.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. AQR Capital Management LLC lifted its position in shares of Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after purchasing an additional 955,284 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in Zimmer Biomet by 3,633.7% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock worth $45,729,000 after buying an additional 451,816 shares during the last quarter. Freestone Grove Partners LP grew its position in shares of Zimmer Biomet by 29.2% in the 3rd quarter. Freestone Grove Partners LP now owns 925,937 shares of the medical equipment provider’s stock worth $91,205,000 after acquiring an additional 209,268 shares in the last quarter. Danske Bank A S bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $12,442,000. Finally, Man Group plc raised its position in shares of Zimmer Biomet by 2,617.9% during the 2nd quarter. Man Group plc now owns 116,000 shares of the medical equipment provider’s stock valued at $10,580,000 after acquiring an additional 111,732 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Stifel Nicolaus set a $110.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. The Goldman Sachs Group lowered Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price for the company. in a research note on Friday, January 9th. UBS Group dropped their target price on Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating on the stock in a report on Wednesday, January 28th. BTIG Research restated a “buy” rating and issued a $112.00 price target on shares of Zimmer Biomet in a report on Thursday, January 8th. Finally, Citigroup dropped their price objective on shares of Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $106.10.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.